Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 95

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 95
---
 2024 Warrants and August 2024 Warrants) to such holders.

October 2024 Registered Direct Offering and Concurrent Private Placement

On October 21, 2024, we issued to certain institutional investors (i) in a registered direct offering, 2,048,294 shares of our Common Stock, and (ii) in a concurrent private placement, common warrants to purchase an aggregate of 2,662,782 shares of Common Stock, with an exercise price of $1.50, pursuant to a securities purchase agreement, dated October 18, 2024, that we entered into with such institutional investors, and received aggregate gross proceeds from the offerings of approximately $2.7 million, before deducting placement agent fees and other offering expenses.

August 2024 Warrant Inducement, Registered Direct Offering and Concurrent Private Placement

On August 5, 2024, pursuant to the terms of the warrant inducement agreement, dated August 2, 2024 (the “August Inducement Agreement) certain holders of existing warrants, exercised for cash common warrants to purchase an aggregate of up to 1,041,667 shares of Common Stock that we issued on March 8, 2024 (the “March 2024 Warrants”), at the reduced exercise price of $1.25 per share. We received aggregate gross proceeds of approximately $1.3 million, before deducting advisory fees and other expenses payable by us. In consideration of the immediate exercise of the March 2024 Warrants by the holders thereof in accordance with the August Inducement Agreement, we issued unregistered common warrants to purchase an aggregate of up to 1,302,082 shares of Common Stock (120% of the number of shares of Common Stock issuable upon exercise of the March 2024 Warrants) to such holders.

On August 5, 2024, we also issued to an institutional investor (i) in a registered direct offering, 360,000 shares of Common Stock, and (ii) in a concurrent private placement, warrants to purchase an aggregate of 450,000 shares of Common Stock, with an exercise price of $1.50. We received aggregate gross proceeds from the offerings of approximately $450,000, before deducting fees payable to the placement agent and other estimated offering expenses.

March 2024 Registered Direct Offering and Concurrent Private Placement

On March 8, 2024, we issued to certain investors, pursuant to a Securities Purchase Agreement (1)